A股異動 | 合鍛智能(603011.SH)再次漲停 錄得三連板 公司新材料仍處於研發階段
格隆匯2月20日丨合鍛智能(603011.SH)今日再次高開拉漲停,錄得三連板。現報6.24元,暫成交1.39億元,最新總市值28.27億元。連續2個漲停的合鍛智能(603011.SH)昨日稱,被納入安徽省新型冠狀病毒感染肺炎疫情防控重點保障企業名單。希望能緩解口罩生產所需熔噴布的缺口。值得注意的是,公司微納複合防護抗菌新材料及裝備的研製仍處於實驗研發階段,未來存在一定的不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.